



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 3, 2019

J. Mel Sorensen, M.D.
Chief Executive Officer
Galera Therapeutics, Inc.
2 W Liberty Blvd #100
Malvern, PA 19355

Re: Galera Therapeutics, Inc.
Amendment No. 2 to Draft Registration Statement on Form S-1
Submitted on August 9, 2019
CIK No. 0001563577

Dear Dr. Sorensen:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 2 to Draft Registration Statement on Form S-1

Prospectus Summary

Risks Associated with Our Business, page 6

1. Please disclose here that your INDs for GC4419 were placed on clinical hold.

Business

ROMAN Trial (Phase 3), page 108

2. We note that your INDs for GC4419 have been placed on clinical holds. Please disclose if you anticipate that these clinical holds will be lifted and if so when. Please also describe what conditions need to be met for the FDA to lift the clinical holds.

J. Mel Sorensen, M.D.
Galera Therapeutics, Inc.
September 3, 2019
Page 2

You may contact Christine Torney at (202) 551-3652 or Lisa Vanjoske at (202) 551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Tonya K. Aldave at (202) 551-3601 or Dietrich King at (202) 551-8071 with any other questions.

Sincerely,

Division of Corporation Finance
Office of Healthcare & Insurance

cc: Nathan Ajiashvili, Esq.